Healthcare Industry News: CollaGenex Pharmaceuticals
News Release - July 19, 2006
Magen BioSciences, Inc. Announces Brian M. Gallagher Joins as President and CEOCAMBRIDGE, Mass., July 19 (HSMN NewsFeed) -- Magen BioSciences, Inc. today announced that Brian M. Gallagher, Ph.D., has joined as President and CEO of the Cambridge, Massachusetts-based specialty pharmaceutical company, effective July 17, 2006.
"We are delighted that we have been able to attract Brian Gallagher to Magen as our CEO," said Christopher Walsh, Ph.D., National Academy of Sciences member, Harvard Medical School professor, and Magen board member. "Brian has a unique blend of managerial intelligence, leadership skills, and industry experience. This interface of discovery and development experience makes him a tremendous asset as we build our company."
Dr. Gallagher comes to Magen with broad industry experience, most recently as Chairman and CEO of CollaGenex Pharmaceuticals, a publicly traded dermatology, specialty pharmaceutical company. Prior to that, he was with Bristol-Myers Squibb, where he held a number of executive positions, including President of Squibb Diagnostics. He also served with E.I. DuPont deNemours, where he held several research, development, marketing, and business management positions.
Phillip Sharp, Ph.D., Nobel Laureate, MIT professor and Magen board member commented, "Brian Gallagher is a proven CEO in the pharmaceutical and biotechnology industry. His scientific knowledge and business expertise are reflected in his history of success in bringing pharmaceutical products to the market. That experience, together with the strong science behind Magen, makes this a truly exciting company."
About Magen BioSciences
Magen BioSciences is a specialty pharmaceutical company currently focused on developing proprietary medical therapies for the dermatology market. Magen was cofounded in March 2006 by Richard Aldrich, David Fisher, M.D. Ph.D, Phillip Sharp, Ph.D., David Shaw, Christopher Walsh, Ph.D. and Christoph Westphal, M.D., Ph.D. Investors include ARCH Venture Partners, TVM Capital, and Venrock Associates with participation from Alexandria Real Estate and Lux Capital.
Source: Magen BioSciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.